Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03930758
Other study ID # HUM32227/ HUM32700
Secondary ID R15DK082800M01RR
Status Completed
Phase N/A
First received
Last updated
Start date October 8, 2009
Est. completion date December 20, 2012

Study information

Verified date April 2019
Source University of Michigan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The two specific aims of the study were to determine whether:

1. Greater mechanical loading of downhill exercise will increase the osteogenic index (ratio between CICP, the marker of bone formation (c-terminal propeptide of type I collagen, and CTX, the marker of bone resorption (c terminal telopeptide of type I collagen)) to a greater extent than uphill exercise that provides lower ground-reaction force;

2. Exercise after the meals will induce greater osteogenic response than exercise pefore the meals as it is known that meal eating during daytime inhibits bvone resorption markers.


Description:

The study addresses the problem that postmenopausal women with type 2 diabetes have a higher incidence of bone breaks despite their often normal bone mineral density (BMD).

The investigators pursued two hypotheses, that:

1. 40-minute bout of downhill exercise will increase the CICP/CTX osteogenic index to a greater extent than the same amount of uphill exercise; and

2. Performing exercise one hour after the meals will be more osteogenic than exercise before the meals.

Subjects were 15 postmenopausal women with type 2 diabetes, age 57.7 years, BMI 27.2 kg/m2 who were randomly assigned to two out of 5 trials:

Uphill exercise before the meals (UBM), Uphill exercise after the meals (UAM), Downhill exercise before the meals (DBM), Downhill exercise after the meals (DAM), and Sedentary, no-exercise, trial (SED). All subjects signed an informed consent approved by the University of Michigan Medical School Institutional Review Board. Subjects had their BMD measured with DXA at the outset.

Weight-maintenance meals contained 50% carbohydrate, 15% protein, and 25% fat and were provided at 10 h and 17 h. Exercise (40 minutes at 50% of maximal effort) on either uphill (+6o slope) or downhill treadmill (-6o slope) was performed either before the two meals, at 9 h and 16 h, respectively, or after the meals. at 11 h and 18 h, respectively.

Blood was drawn through an intravenous catheter from ante-cubital vein at hourly intervals between 8 and 20 h with two additional blood draws at 0 h and 6 h the next morning. Blood was treated with protease inhibitors, and plasma, frozen at -80o C, was used to measure bone markers, CICP, CTX, osteocalcin , and bone-specific alkaline phosphatase using Millipore chemoluminescen reagents, glucose by glucose oxidase, and hormones insulin, cortisol, parathyroid hormone (PTH) , and growth hormone (GH) by radio-immunoassays..

Mixed-model ANOVA was used for analysis of outcome measures where the trial procedures served as fixed variable and individual subjects as intercept variables.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date December 20, 2012
Est. primary completion date December 5, 2012
Accepts healthy volunteers No
Gender Female
Age group 50 Years to 65 Years
Eligibility Inclusion Criteria:

postmenopausal type-2 diabetes melllitus age between 50 and 65 exercise less than 20 minutes three times a week

Exclusion Criteria:

metabolic disease other than type-2 diabetes and hormonally-corrected hypothyroidism musculo-skeletal disability that would preclude exercise smoker do not meet inclusion criteria

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Behavior intervention of uphill exercise
40 minutes of uphill exercise
Dietary intervention of exercise before the meal
40 minutes of uphill exercise completed 1 h before the meal
Dietary intervention of uphill exercise
40 minutes of uphill exercise
Dietary intervention of exercise after the meal
40 minutes of uphill exercise started 1 hour after gthe meal
Behavior intervention of downhill exercise
40 minutes of downhill exercise
Dietary intervention of exercise before the meal
40 minutes of downhill exercise completed 1 hour before the meal
Behavioral intervention of downhill exercise
40 minutes of downhill exercise
Dietary intervention of exercise after the meal
40 minutes of downhill exercise started 1 hour after the meal
Behavioral intervention of sedentary no-exercise trial
Sedentary no-exercise trial
Dietary intervention of eating two meals
Meals eaten at 10 and 17 h during a sedentary trial

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
University of Michigan National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Wisconsin, La Crosse

Outcome

Type Measure Description Time frame Safety issue
Primary C-terminal propeptide of type I collagen Change over time in plasma concentration of c-terminal propeptde of type 1 collagen (ng/ml) Hourly over 12 hours from the start of the trial, then at 16 hours, and at 22 hours, after the start of the trial
Primary C-terminal telopeptide of type 1 collagen Change over time in plasma concentration of c-terminal telopeptide of type 1 collagen (ng/ml) Hourly over 12 hours from the start of the trial, then at 16 hours, and at 22 hours, after the start of the trial
Primary Osteocalcin Change over time in plasma concentration of osteocalcin (ng/ml) Hourly over 12 hours from the start of the trial, then at 16 hours, and at 22 hours, after the start of the trial
Primary Bone-specific alkaline phosphatase Change over time in plasma concentration of bone-specific alkaline phosphatase (ng/ml) Hourly over 12 hours from the start of the trial, then at 16 hours, and at 22 hours, after the start of the trial
Secondary Insulin Change over time in plasma concentration of insulin (µU/ml) Hourly over 12 hours from the start of the trial, then at 16 hours, and at 22 hours, after the start of the trial
Secondary Parathyroid hormone Change over time in plasma concentration of parathyroid hormone (ng/ml) Hourly over 12 hours from the start of the trial, then at 16 hours, and at 22 hours, after the start of the trial
Secondary Cortisol Change over time in plasma concentration of cortisol (m/L) Hourly over 12 hours from the start of the trial, then at 16 hours, and at 22 hours, after the start of the trial
Secondary Growth hormone Change over time in plasma concentration of growth hormone (ng/ml) Hourly over 12 hours from the start of the trial, then at 16 hours, and at 22 hours, after the start of the trial
Secondary Glucose Change over time in plasma concentration of glucose (mg/dl) Hourly over 12 hours from the start of the trial, then at 16 hours, and at 22 hours, after the start of the trial
Secondary Dual-energy X-ray radiography Whole-body dual-energy X-ray radiography scan A week prior to the study baseline
Secondary Novel Pedar Mechanosensitive shoe inserts for measurement of ground reaction force During two one-hour bouts of the exercise intervention
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2